ROLE OF PROPHYLACTIC TRANEXAMIC ACID IN PREVENTION OF POST-PARTUM HEMORRHAGE IN ELLSCS

Launched by PATEL HOSPITAL, PAKISTAN · May 25, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating whether a medication called tranexamic acid can help prevent heavy bleeding after childbirth, known as postpartum hemorrhage (PPH), in women undergoing elective lower segment cesarean sections (ELLSCS). In the study, participants will be randomly divided into two groups: one group will receive tranexamic acid, while the other group will receive a placebo, which is a substance with no active medication. The goal is to see if tranexamic acid can effectively reduce the risk of PPH.

To be eligible for this trial, women must be pregnant with a single baby and considered to be at low risk for PPH. However, those who have certain medical conditions, a history of heavy bleeding after previous births, or complications like multiple pregnancies will not be included. If you choose to participate, you will be part of a carefully monitored study where your experience will help researchers understand the potential benefits of this medication for future mothers. Right now, the trial is not yet recruiting participants, so there is no immediate action needed.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women with singleton pregnancy and low risk for PPH admitted for ELLSCS
• Exclusion Criteria:
• • Women with medical disorder or complex pregnancy.
• • Women with history of PPH.
• • Women with bleeding disorder.
• • Abnormal placentation (MAP, placenta previa)
• • Multiple pregnancy.